

10/510018

DT04 Re CT/PTO 0 1 OCT 2004
PATENT

Attorney Docket No. Le A 35 945

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stefan Golz, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2003/002962

Title: Diagnostics and Therapeutics for Diseases Associated with Neuropeptide FF Receptor 2 (NPFF2)

**MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Susan M. Pellegrino
Reg. No.: 48,972
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Telephone: (203) 812-6450
Facsimile: (203) 812-6459

Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Serial No.

Art Unit

Filing Date

10/5/00
Att. Doc. No. 18
Le A 35 945

INFORMATION DISCLOSURE CITATION

Applicant(s)

Stefan GOLZ, et al.

U.S. PATENT DOCUMENTS

| * | | DOCUMENT NO. | | | | | | | DATE (MM/DD/YY) | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|---|----|--------------|---|---|---|---|---|---|--------------------|---------------|-------|---------------|----------------------------------|
| | U1 | 6 | 2 | 6 | 2 | 2 | 4 | 6 | 07/17/2001 | Gerald et al. | 536 | 23.5 | 02/22/1999 |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

FOREIGN PATENT DOCUMENTS

| * | | DOCUMENT NO. | | | | | | | DATE (DD/MM/YY) | COUNTRY | PRIMARY CLASS | SUB- CLASS | TRANSLATION | |
|---|----|--------------|---|---|---|---|---|---|--------------------|---------|------------------|---------------|-------------|----|
| | | | | | | | | | | | | | YES | NO |
| | F1 | 0 | 1 | 5 | 7 | 1 | 8 | 8 | 09/08/01 | WO | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

| | |
|----|---|
| R1 | Lecron, J.-C., et al., "Modulation of human lymphocyte proliferation by FLFQPQRFamide, a FMRFamide-like peptide with anti-opiate properties", J. Neuroimmunology, <u>38</u> (1-2): 1-8 (1992) |
| R2 | Kotani, M., et al., "Functional characterization of a human receptor for neuropeptide FF and related peptides", British Journal of Pharmacology, <u>133</u> (1): 138-144 (2001) |
| | |
| | |
| | |
| | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.